<DOC>
	<DOCNO>NCT00604461</DOCNO>
	<brief_summary>The purpose research study evaluate effective combination Carboplatin , Bevacizumab ( Avastin™ ) , Pemetrexed ( Alimta™ ) treatment patient Malignant Pleural Mesothelioma ( MPM ) . A combination cisplatin pemetrexed consider standard disease typically protocol patient would receive cisplatin carboplatin pemetrexed standard care . The planned length study ( first patient screen last patient enrol ) 24 month . The planned length entire study ( enrollment period + treatment period + follow-up period least 12 month ) 36 month .</brief_summary>
	<brief_title>Carboplatin , Bevacizumab Pemetrexed First-Line Treatment Patients With Malignant Pleural Mesothelioma ( MPM )</brief_title>
	<detailed_description>This planned Phase I/II dose escalation study . Patients enrol cohort 3 . Eligible patient unresectable pleural mesothelioma receive frontline treatment consist carboplatin AUC 5 , bevacizumab 15 mg/kg , pemetrexed 500 mg/m^2 every 21 day ( Tier-1 ) . Dose escalation continue achieve target dosage use carboplatin AUC 6 ( Tier-2 ) . After maximum 6 treatment cycle , non-progressing patient receive maintenance therapy bevacizumab pemetrexed every 21 day complete 1-year total treatment duration .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patient must histologically prove diagnosis Malignant Pleural Mesothelioma ( MPM ) Patient must MPM measurable disease . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Patient must adequate renal function serum creatinine level le 1.5 mg/dl patient calculate creatinine clearance 40ml/min . Patient must adequate hepatic function serum bilirubin level less 3mg/dl , alkaline phosphatase , ALT AST less five time upper limit normal Patient must also evidence adequate bone marrow function absolute neutrophil count 1500 cell per deciliter platelet count 100,000 per deciliter . Patients must 28 day since prior open biopsy ; 7 day since prior fineneedle aspiration ; 7 day since prior core biopsy ; 28 day since prior surgery . Patients must able take dexamethasone , folic acid , vitamin B12 supplementation . All patient must sign informed consent detail investigational nature study accordance institutional federal guideline . Patients clinically significant pleural effusion ascites ( symptomatic detectable clinical exam ) effusion drain prior enrollment clinical trial . Patients hypercalcemia ( correct calcium 11 mg/dl ) exclude . Patients history hemoptysis , haematemesis , coagulopathy thrombosis exclude . Patients require anticoagulation reason exclude . History palliative radiation therapy within 2 week Blood pressure &gt; 160/100 mmHg , despite adequate antihypertensive use . Currently ongoing unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure . History stroke within 6 month Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day initiation treatment , anticipation need major surgical procedure course study Minor surgical procedure fine needle aspiration core biopsy within 7 day prior day initiation treatment . Pregnant ( positive pregnancy test ) lactate Urine calculate creatinine clearance less 40ml/minute . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Inability comply study and/or followup procedure Laboratory Values : Patient must adequate renal function serum creatinine level le 1.5 mg/dl patient calculate creatinine clearance 40ml/min . Patient must adequate hepatic function serum bilirubin level le 3 mg/dl , alkaline phosphatase , ALT AST less five time upper limit normal Patient must also evidence adequate bone marrow function absolute neutrophil count 1 , 500 cell per deciliter platelet count 100,000 per deciliter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Carboplatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Alimta</keyword>
</DOC>